Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Propranolol for Focal Refractory Epilepsy
NCT06719804Phase 1Not yet recruiting
- Sponsor
- Xuanwu Hospital
- Start
- Dec 2024
- Primary completion
- Dec 2027
- Modality
- Small Molecules
01
Overview
Phase 1, open-label, single-arm trial of propranolol in Focal Epilepsy (FE), sponsored by Xuanwu Hospital. Primary endpoints: Percent Change From Baseline in Seizure Frequency Per 28 Days and Seizure Responder Rate at 12 months. Planned start Dec 2024; status: not yet recruiting.
02
Drugs
propranolol
03
Conditions
Focal Epilepsy (FE)
Beyond the preview
Go deeper on NCT06719804.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06719804.